You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 192 Clinicopathologic, genomic and immunophenotypic features and outcomes to immune checkpoint inhibitors in patients with mucinous lung adenocarcinoma

Citation Tools

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Biomarkers, Immune Monitoring and Novel Technologies
192 Clinicopathologic, genomic and immunophenotypic features and outcomes to immune checkpoint inhibitors in patients with mucinous lung adenocarcinoma

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Federico AD, Ricciuti B, Alessi JV, et al
192 Clinicopathologic, genomic and immunophenotypic features and outcomes to immune checkpoint inhibitors in patients with mucinous lung adenocarcinoma
Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.0192